The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

July 16, 2002

Primary Completion Date

April 28, 2004

Study Completion Date

April 28, 2004

Conditions

Diabetic Nephropathy

Interventions

DRUG

LY333531

Trial Locations (15)

La Jolla

Walnut Creek

Jacksonville

Atlanta

Chicago

Lexington

Baltimore

Waltham

Minneapolis

St Louis

New York

Greenville

Dallas

Seattle

Spokane

All Listed Sponsors

lead

Chromaderm, Inc.

INDUSTRY

NCT00044148 - The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter